NOR-TEST

Norwegian Tenecteplase Stroke Trial

A randomized controlled trial of
tenecteplase vs. alteplase
in acute ischemic stroke

Nicola Logallo MD PhD

Hypothesis & Methods

Hypothesis

- TNK 0,4 mg/kg has superior efficacy
- TNK 0,4 mg/kg is safe

Design

- Randomized Open label Blinded Endpoints
- Tenecteplase 0.4 mg/kg vs. alteplase 0.9 mg/kg
- Randomisation 1:1

Inclusion criteria

- Ischemic stroke patients > 18 years
- Mesurable NIHSS deficit
- Treatment start <4.5 hours

Study endpoints

- Primary endpoint
  - Outcome at 3 months (mRS 0-1)
- Secondary endpoints
  - Safety (SICH / ICH)
  - NIHSS at 24 hours
  - mRS 3 months (ordinal shift)



NOR-TEST

Norwegian Tenecteplase Stroke Trial

NORSTROKE

Norwegian Stroke Research Co-operation

Bodö
Trondheim
Molde
Förde
Bergen
Haugesund
Stavanger
Tönsberg
Skien
Drammen
Oslo
Akershus
Baerum